Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 in Advanced Solid Tumors
NCT03994484Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ha121-28 in solid tumor (advanced stage) (8 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
ha121-28
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03994484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994484.